Trastuzumab combined with chemotherapy is currently a novel recommended treatment of HER2-positive breast cancer patients.260 Besides, the other emerging anti-HER2 targeting drugs may serve as new standards in the future.261 Previous pioneering studies have led the foundation of our understanding of anti-HER2 therapies, and some new concepts should be highly valued.176,262. Here, ERBB2 is linked to breast carcinoma.